Kenvue Inc. (KVUE) · Oct 30, 2026 · Earnings

Kenvue earnings in line as margins improve, Skin Health lags

In line — Adjusted EPS $0.29 vs ~$0.29 consensus

Kenvue’s third-quarter earnings were broadly in line with expectations: sales edged ahead, margins expanded, but Skin Health remained soft.

Kenvue is a standalone consumer-health company trying to improve growth and margins while reshaping its cost base ahead of its pending combination with Kimberly-Clark. The prior quarter had already established a pattern of sales growth and operational improvement, with no forward guidance because of the transaction.

The quarter met the bar, rather than reset it. Third-quarter sales of $3.886 billion were slightly ahead of the published consensus near $3.86 billion, while adjusted diluted EPS of $0.29 was essentially in line with consensus near $0.29. That makes this a steady execution quarter, not a meaningful earnings surprise. The company delivered its fourth consecutive quarter of net and organic sales growth. 〔0〕

Q3 2026Q3 2025Consensus
Net sales (Income Statement)$3,886M (+3.2%)$3,764M~$3,860M
Adjusted diluted EPS (EPS reconciliation)$0.29 (+3.6%)$0.28~$0.29
Organic sales growth (Sales growth table)2.9%——
Adjusted operating margin (Adjusted operating income reconciliation)21.9% (+0.4 pts)21.5%—

The better part of the release is operating leverage. Adjusted operating margin expanded to 21.9% from 21.5%, helped by productivity, supply-chain savings, tariff refunds, pricing, and cost optimization. Reported operating margin improved even more, to 18.2% from 16.7%, although the comparison still includes restructuring and transaction-related charges.

Growth remains uneven across the portfolio. Self Care was the clear engine, with organic sales up 5.4%, while Essential Health grew 2.5%. Skin Health and Beauty was effectively stagnant on reported sales and declined 0.5% organically as U.S. distribution losses and European retailer negotiations outweighed gains from Hair Care. That mix matters: Kenvue is improving execution, but not yet broadly accelerating across all major franchises.

Cash generation gives the transformation more credibility. Nine-month free cash flow rose to $1.6 billion from $1.0 billion, while debt declined to $8.2 billion from $8.5 billion at year-end. The company also recorded $188 million of restructuring and operating-model costs through nine months against its approximately $250 million full-year 2026 target, so the savings program is active but still carrying meaningful execution costs.

The Kimberly-Clark deal remains the dominant external variable. Kenvue incurred $28 million of pending-transaction costs in the quarter and $60 million year to date, while continuing to withhold formal forward guidance. The transaction was already widely known, so this filing adds operating detail rather than changing the strategic situation.

Bottom line: Kenvue is executing the turnaround plan with improving margins, cash flow, and core-category growth, but Q3 was broadly expected rather than a surprise. The business story is progressing, not materially re-rated by this filing; the bigger next change comes from completing the Kimberly-Clark combination.

9M 20269M 2025
Free cash flow (Cash Flow reconciliation)$1.6B (+60%)$1.0B
Total debt (Balance sheet summary)$8.2B$8.5B
Restructuring and operating-model costs (Restructuring table)$188M$232M

What to watch next

Kimberly-Clark transaction closing

Original filing on SEC EDGAR

More Kenvue Inc. news

Kenvue earnings in line as margins improve, Skin Health lags | KVUE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.